ArticleBMC veterinary research2025
The impact of in ovo injection of cluster bean peptide on hatchability, growth performance, carcass characteristics, digestive enzymes, and blood indices of broiler chickens.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The administration of bioactive short peptides through in ovo feeding can improve the overall health and performance of broiler chickens for the poultry industry. Additionally, bioactive peptides possess biological features that have the potential to be beneficial in preventing many metabolic illnesses; hence, the ingestion of these peptides holds the potential to be advantageous for human health. In light of this, the current work aimed to study the impacts of in ovo feeding during the late stages of embryonic development with cluster bean peptide (CBP) on the hatchability, productive performance, lipid profile, liver and kidney functions, immunological response, and antioxidant status of broilers. Six hundred and forty-eight (648) fertilized Ross 308 broiler breeder eggs were used in this study. To remove infertile eggs and dead embryos, the eggs were manually candled on 7 and 17 day of incubation (DOI). On the 18.5th DOI, the eggs were separated into four treatment groups (156 eggs/each), and the first group did not receive any treatment and represented the negative control (NC). Meanwhile, the other treatment groups were injected into the amnion membrane. The second group was only subjected to needle penetration and represented the positive control (PC). The third group was denoted by the letter T1 and received an injection of 1 mg CBP/egg. The fourth group was denoted by the letter T2 and received an injection of 2 mg CBP/egg. In ovo feeding by CBP exhibited significant improvements in the body weight of newly hatched chicks, particularly at the 2 mg CBP level. The administration with CBP did not significantly affect the carcass characteristics of 28-day-old broilers. In ovo-administrated groups with CBP, higher plasma concentrations of total protein and its fractions were observed at hatch and on day 28 of age. In ovo treatment with CBP, blood lipid profile parameters significantly improved at hatch and 28 days of age. Liver and kidney function parameters were improved in response to the in ovo administration with CBP in newly hatched chicks and on day 28 of age. Blood levels of glutathione (GSH) and superoxide dismutase (SOD) were considerably higher in the in ovo-administered groups with CBP; while levels of malondialdehyde (MDA) were significantly reduced due to CBP administration. The activity of digestive enzymes in blood plasma was decreased in newly hatched chicks but increased in 28-day-old broilers in response to in ovo administration with CBP. There was an improvement in the immunological response of hatched chicks from groups injected with CBP, particularly the T2 group (2 mg CBP), as evidenced by increased IgM and IgG levels. The findings presented here indicate that the in ovo administration with CBP, specifically at a dosage of 2 mg, improved growth performance and immune and antioxidant functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.